27 min
Ep. 42: Creating drugs at the speed of AI The Latest Dose
-
- Teknologi
Artificial intelligence (AI) is one of the most discussed technologies across all industries. Life science professionals working in the pharmaceutical industry strive to improve people’s lives tackling incredibly complex diseases. Drug development is often perceived as slow. As the pharma industry looks to improve the drug development process AI promises nothing less than a revolution.
Can AI help speed up the drug development process? Identify new drug molecules that have so far eluded scientists?
Will AI–designed medicines be safe for people? Have the desired effect on the disease? Meet the rigorous regulatory standards to actually be approved for human use?
In this episode, Andreas Busch, Ph.D., Chief Innovation Officer at Absci will answer these questions and shares the value generative-AI is providing drug development today.
--------------------------------------------------------
Episode Transcript:
00;00;00;00 - 00;00;31;24
Hi, everyone, and welcome to the Latest Dose, the podcast that explores the depth of innovation and human compassion in clinical research. I'm your host, Katherine Vandebelt, global vice president of Clinical Innovation at Oracle Health Sciences. Artificial Intelligence, AI, is one of the most popular technologies on the planet, and I find it referenced in most, if not all, industries.
00;00;31;26 - 00;00;59;16
Those of us working in the pharmaceutical industry strive to improve people's lives. Can AI help scientists develop better medicines faster? Human bodies are incredibly complex. Drug development is slow. Since I've been engaged in drug development, many people, teams, organizations, and companies have been working tirelessly to improve the drug development process, the promise, is nothing more than a revolution for the pharmaceutical industry.
00;00;59;19 - 00;01;26;21
The March 8th, 2023 Politico article states “nearly 270 companies are working in AI driven drug discovery”. Let's start learning more about AI driven drug discovery and discuss if or when the promise of AI will be realized. Can AI help speed up the drug development process? Identify new drug molecules that have so far eluded scientists?
00;01;26;23 - 00;02;02;02
Can AI-designed medicines, be safe for people? Have the desire effect on the disease? Meet the rigorous regulatory standards to actually be approved for human use? You know, many of these questions can be answered today with my guest, Andreas Busch, Ph.D. Chief Information Officer at Absci. Andreas brings substantial R&D expertise to Absci’s leadership, a world renowned leader in drug discovery and has led R&D efforts for some of the globe's top pharma companies, including Sanofi, Bayer, and Shire.
00;02;02;05 - 00;02;37;05
Andreas’ leadership has resulted in over ten commercial drugs starting from bench to FDA approval, with several more in late stage clinical development. Andreas holds the title of Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe University in Frankfurt, Germany, where he also received his Ph.D. in pharmacology. Andreas loves, real football a.k.a soccer, enjoys riding his motorcycle through Alps and playing with his beloved dogs Zorro.
00;02;37;07 - 00;03;04;28
Welcome, Andreas. Thank you for making the time to speak with me today. Hey, it's a pleasure talking to you Katherine. So, Andreas I have been taught that artificial intelligence, referred to as AI, are computer intelligence programs that can handle real-time problems and help organizations and everyday people achieve their goal. And AI is obviously a topic of discussion these days and getting way more attention with the release of the articles around ChatGPT.
00;03;04;28 - 00;03;33;22
Today I'd like to focus our discussion on generative AI, but I thought it would be helpful if you could share with me what's important for me to actually know about this type of AI. I'm glad to talk about it
Artificial intelligence (AI) is one of the most discussed technologies across all industries. Life science professionals working in the pharmaceutical industry strive to improve people’s lives tackling incredibly complex diseases. Drug development is often perceived as slow. As the pharma industry looks to improve the drug development process AI promises nothing less than a revolution.
Can AI help speed up the drug development process? Identify new drug molecules that have so far eluded scientists?
Will AI–designed medicines be safe for people? Have the desired effect on the disease? Meet the rigorous regulatory standards to actually be approved for human use?
In this episode, Andreas Busch, Ph.D., Chief Innovation Officer at Absci will answer these questions and shares the value generative-AI is providing drug development today.
--------------------------------------------------------
Episode Transcript:
00;00;00;00 - 00;00;31;24
Hi, everyone, and welcome to the Latest Dose, the podcast that explores the depth of innovation and human compassion in clinical research. I'm your host, Katherine Vandebelt, global vice president of Clinical Innovation at Oracle Health Sciences. Artificial Intelligence, AI, is one of the most popular technologies on the planet, and I find it referenced in most, if not all, industries.
00;00;31;26 - 00;00;59;16
Those of us working in the pharmaceutical industry strive to improve people's lives. Can AI help scientists develop better medicines faster? Human bodies are incredibly complex. Drug development is slow. Since I've been engaged in drug development, many people, teams, organizations, and companies have been working tirelessly to improve the drug development process, the promise, is nothing more than a revolution for the pharmaceutical industry.
00;00;59;19 - 00;01;26;21
The March 8th, 2023 Politico article states “nearly 270 companies are working in AI driven drug discovery”. Let's start learning more about AI driven drug discovery and discuss if or when the promise of AI will be realized. Can AI help speed up the drug development process? Identify new drug molecules that have so far eluded scientists?
00;01;26;23 - 00;02;02;02
Can AI-designed medicines, be safe for people? Have the desire effect on the disease? Meet the rigorous regulatory standards to actually be approved for human use? You know, many of these questions can be answered today with my guest, Andreas Busch, Ph.D. Chief Information Officer at Absci. Andreas brings substantial R&D expertise to Absci’s leadership, a world renowned leader in drug discovery and has led R&D efforts for some of the globe's top pharma companies, including Sanofi, Bayer, and Shire.
00;02;02;05 - 00;02;37;05
Andreas’ leadership has resulted in over ten commercial drugs starting from bench to FDA approval, with several more in late stage clinical development. Andreas holds the title of Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe University in Frankfurt, Germany, where he also received his Ph.D. in pharmacology. Andreas loves, real football a.k.a soccer, enjoys riding his motorcycle through Alps and playing with his beloved dogs Zorro.
00;02;37;07 - 00;03;04;28
Welcome, Andreas. Thank you for making the time to speak with me today. Hey, it's a pleasure talking to you Katherine. So, Andreas I have been taught that artificial intelligence, referred to as AI, are computer intelligence programs that can handle real-time problems and help organizations and everyday people achieve their goal. And AI is obviously a topic of discussion these days and getting way more attention with the release of the articles around ChatGPT.
00;03;04;28 - 00;03;33;22
Today I'd like to focus our discussion on generative AI, but I thought it would be helpful if you could share with me what's important for me to actually know about this type of AI. I'm glad to talk about it
27 min